Table 2.

Adverse events during chemoradiation with panitumumab (maximum grade of each AE per patient) during the chemoradiation with panitumumab (first 43 days)

Cohort 1.0 mg/kg (n = 3)Cohort 1.5 mg/kg (n = 6)Cohort 2.0 mg/kg (n = 5)
AE, n (%)Grade 1/2Grade 3/4Grade 1/2Grade 3/4Grade 1/2Grade 3/4
Blood/bone marrow
 Thrombocytopenia2 (33)
 Neutropenia2 (33)2 (33)1 (20)
Constitutional symptoms
 Fatique (asthenia, lethargy, malaise)2 (67)4 (67)1 (17)2 (40)
 Weary legs1 (17)
 Fever1 (33)2 (33)
 Weight loss1 (17)2 (40)
 Insomnia1 (20)
Neurology
 Dizziness when getting up1 (20)
 Neuropathy1 (17)
Syndromes
 Flu like syndrome1 (17)
Pulmonary/upper respiratory
 Cough1 (17)
 Hiccups1 (17)1 (20)
Gastrointestinal
 Nausea1 (33)5 (83)1 (17)3 (60)1 (20)
 Vomiting5 (83)1 (17)4 (80)
 Stomach complaints1 (33)1 (17)
 Anorexia1 (33)4 (67)4 (80)
 Flatulence1 (17)
 Constipation3 (50)
 Taste alteration1 (17)
 Diarrhea1 (17)1 (20)
 Pyrosis1 (20)
Pain
 Glossodynia1 (33)
 Tumor pain1 (17)
 Pain1 (33)1 (20)
 Abdominal pain1 (33)2 (33)
Dermatology/skin
 Dry skin1 (17)
 Acneiform rash2 (67)2 (33)3 (60)
 Paronychia big toe1 (33)
 Node in groin region1 (33)
Rash1 (33)2 (33)1 (20)
 Red skin (face)1 (17)
 Pruritus/itching1 (20)
 Erythema (face/groin/abdomen)1 (17)
Renal/genitourinary
 Dysuria1 (17)
Hemorrhage/bleeding
 Epistaxis1 (20)
 Gastrointestinal1 (20)
Metabolic/laboratory
 Elevated transaminases1 (17)
 Hypomagnesemia1 (20)
Infection
 Cellulitis1 (33)
 Urinary tract infection1 (17)